INVENTING A NEW
ROADMAP FOR BIOTECH

Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.

FOR NEARLY 30 YEARS, OUR
MISSION HAS BEEN TO USE
THE POWER OF SCIENCE
TO BRING NEW MEDICINES
TO PATIENTS...OVER AND
OVER AGAIN.

Neil Stahl, PhD, Executive VP,
Research and Development


REGENERON BY THE NUMBERS

  • 29

    years of scientific
    leadership
  • 5,500+

    Regeneron employees
    worldwide
  • 730

    employees with
    an MD, PhD or
    PharmD degree
  • 5TH

    Consecutive Year
    in Forbes' Top
    10 Most Innovative
    Companies
  • #1

    ranking in Science
    magazine’s global Top
    Employer survey for four
    of the past six years
  • 5,691

    volunteer hours at 650
    organizations through
    Regeneron in the
    Community & Matching
    Gifts     program in 2016
  • 6

    FDA-approved
    medicines
  • 31%

    annual reduction
    in greenhouse gas
    emissions per
    employee in 2016
  • 100%

    of drug candidates
    invented and
    developed in-house
  • 200,000

    consented individuals
    sequenced by the
    Regeneron Genetics Center
  • 99

    peer-reviewed
    publications
    in 2016
  • 15+

    antibodies in clinical
    trials across multiple
    therapeutic areas

  • Fortune: 100 Best Companies to Work For, 2017

    Science: #1 Top Employer, 2016

    Barron's: World's Best CEOs, 2016

    Forbes: Top 10 Most Innovative Companies, 2013-2017

  • Civic 50: Most Community-Minded Companies, 2017

    MIT Technology Review: 50 Smartest Companies, 2017

    Scrip Award: R&D Team of the Year, 2016

    Shingo Prize (Bronze Medallion): Operational Excellence, 2013

LEADERSHIP

We are the only biopharmaceutical company to be led by physician-scientists for nearly 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

Our leadership

A FOCUS
ON SCIENCE

From our first days, science has remained our central guiding principle.

Our journey